Document is current

Article History

Accepted: 28 March 2023

First Online: 26 May 2023

Declarations

:

: DM, DE and LF performed the analysis and interpretation of the data, drafted the manuscript, approved the final version and agree to be accountable for all aspects of the work. AM reviewed the analysis and interpretation of the data, critically revised the manuscript, approved the final version and agrees to be accountable for all aspects of the work. YM reviewed the analysis and interpretation of the data, drafted and critically revised the manuscript, approved the final version and agrees to be accountable for all aspects of the work. AK performed the analysis and interpretation of the data, critically revised the manuscript, approved the final version and agrees to be accountable for all aspects of the work. MM reviewed the analysis and interpretation of the data, critically revised the manuscript, approved the final version and agrees to be accountable for all aspects of the work.

: This study was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and AstraZeneca, who are co-developing olaparib.

: Lin Fan, Dominic Muston and Matthew Monberg are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Lin Fan is a former employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Adela Mihai is an employee of AstraZeneca. David Elsea, Yang Meng and Adam Kasle are employees of Lumanity, which received funding from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and AstraZeneca, for this work. David Elsea is a former employee of Lumanity, which received funding from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and AstraZeneca, for this work.

: Not applicable.

: Not applicable.

: Not applicable.

: The corresponding author has full access to all the data in the study. Merck is fully committed to providing qualified scientific researchers access to anonymised patient-level data and full clinical study reports from its clinical trials. Qualified researchers with appropriate competencies engaged in rigorous independent scientific research can submit a data request for patient-level data or a full clinical study report. Please see: . AstraZeneca may share anonymised individual patient-level data with qualified researchers from trials of approved products in the USA and European Union. Please see .

: Not applicable.